SCHEMBL228679

SCHEMBL228679

O=C(NC1CCC(CCN2CCC(C(=O)c3ccc(F)c(F)c3)CC2)CC1)C1CCOC1

nearest known ligand 0.56

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 19/20 0.56
DRD3 P35462 19/20 0.56
DRD2 P14416 17/20 0.56
ACKR3 P25106 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL228678 1.00 HTR2A (0.56) HTR2ADRD3DRD2ACKR3
SCHEMBL228964 0.94 DRD3 (0.61) HTR2ADRD3DRD2ACKR3
SCHEMBL229186 0.90 HTR2A (0.58) HTR2ADRD3DRD2
SCHEMBL229187 0.90 HTR2A (0.58) HTR2ADRD3DRD2
SCHEMBL229757 0.90 ACKR3 (0.52) HTR2ADRD3DRD2ACKR3
SCHEMBL229289 0.85 HTR2A (0.57) HTR2ADRD3DRD2
SCHEMBL229031 0.85 HTR2A (0.57) HTR2ADRD3DRD2
SCHEMBL229296 0.85 HTR2A (0.57) HTR2ADRD3DRD2
SCHEMBL229030 0.85 HTR2A (0.57) HTR2ADRD3DRD2
SCHEMBL228670 0.84 HTR2A (0.62) HTR2ADRD3DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS GOBBI LUCA (CH) 2012-01-05 US claimed
US-8415350-B2 Benzoyl-piperidine derivatives as dual modulators of the 5-HT2A and D3 receptors HOFFMANN-LA ROCHE INC. (US) 2013-04-09 US disclosed
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS GOBBI LUCA (CH) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004208-A1 BENZOYL-PIPERIDINE DERIVATIVES AS DUAL MODULATORS OF THE 5-HT2A AND D3 RECEPTORS HTR2A, HTR3A, HTR2C HTR2A 1/4885DRD3 18/4885DRD2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.